Centralda Medical-BGV 2021 Annual report
Acotec Scientific Gets Chinese Drug Regulator's Registration Approvals for Radiofrequency Medical Devices
06:09 AM EDT, 04/19/2022 (MT Newswires) -- Acotec Scientific (HKG:6669) secured registration approvals from China's National Medical Products Administration for its radiofrequency catheter and radiofr
Centro Medical-B: annual results announcement for the year ended December 31, 2021
Coreda Medical-B: notice of Board meeting
Acotec Scientific Says Unaware of Reasons for Drop in Share Price; Shares Fall 4%
01:25 AM EST, 03/10/2022 (MT Newswires) -- Acotec Scientific Holdings (HKG:6669) was unaware of what dragged down the the price of its shares recently, according to a late Wednesday filing. The interv
Acotec Submits Investigational Device Exemption for Ischemia Treatment to US FDA
12:15 AM EST, 02/01/2022 (MT Newswires) -- Acotec Scientific Holdings (HKG:6669) filed an investigational device exemption application to the US Food and Drug Administration for its paclitaxel drug-c
Investment rating and target price of Chinese medicine, R & D, medical equipment, distribution and traditional Chinese medicine stocks in the "Bank of China report" (table)
Morgan Stanley publishes research report For Chinese-funded medicine, research and development, medical equipment, The investment rating and target price of distribution and traditional Chinese medicine stocks are listed as follows: shares | Investment rating | Target price (HK $) Hengduan Pharmaceutical (600276.SH) | increase holdings | 72 yuan INNOVENT BIO (01801.HK) | increase holdings | 95 yuan Wuxi Biologics (02269.HK) | increase holdings | 175 yuan innovative drugs / biomedical stocks and reputation-B (02256.HK) | increase holdings | 13.6 yuan Kang Fang Bio-B (09926. HK) | increased holdings | CNY 68.6% Corning Jerry Pharmaceuticals-B (099)
First Ruida Medical-B (06669.HK): application for marketing license for arteriovenous introduction of DCB products is accepted
First Ruida Medical-B (06669.HK) announced that on January 17 this year, the State Drug Administration accepted its application for registration of AcoArt Orchid&Dhalia for the treatment of arteriovenous stenosis (AVF). AVF is an artificially opened channel between arteries and veins for hemodialysis in patients with end-stage renal disease (ESRD). However, due to periodic trauma and hemodynamic changes, the vessel is easy to cause stenosis, and DCB can effectively treat the stenosis.
Xianruida Medical-B (06669) fell 1.2% to 10.580 yuan, a 52-week low.
Phoenix New Media Hong Kong shares | as of 09:30, the first Ruida Medical-B (06669) was 1.2% lower than yesterday's closing price, and is now at 10.580 yuan, a 52-week low. The turnover was 1000 shares with a turnover of HK $10600.
Xianruida Medical-B (06669) fell 0.60% to 10.780 yuan, a 52-week low.
Phoenix New Media Hong Kong shares | as of 14:01, the first Ruida Medical-B (06669) was 0.60% lower than yesterday's closing price, and is now at 10.780 yuan, a 52-week low; trading volume of 232000 shares with a turnover of HK $2.5439 million.